Please use this identifier to cite or link to this item:
Title: Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes.
Authors: Ng E
Shaw JE
Wood A
Maple-Brown LJ
Hare MJL
Citation: Aust J Gen Pract. 2022 Jul;51(7):513-518. doi: 10.31128/AJGP-07-21-6057.
Abstract: BACKGROUND: Type 2 diabetes (T2D) is a national health priority. Its rising prevalence is accompanied by a high burden of diabetes-related complications, many of which are preventable. Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety. These advances have increased the complexity of prescribing decisions in T2D. OBJECTIVE: This review provides clinicians with relevant evidence and practical advice concerning glucagon-like peptide-1 receptor agonists (GLP1-RAs) in T2D. DISCUSSION: The Royal Australian College of General Practitioners recommends GLP1-RAs as an option for second-line therapy in T2D. GLP1-RAs contribute to weight loss and glycated haemoglobin reduction. GLP1-RAs also reduce incidence of cardiovascular events in selected populations, and available evidence suggests renoprotective effects. Common adverse effects include gastrointestinal symptoms, especially in the weeks following treatment initiation. GLP1-RAs should be considered for people with T2D at high cardiovascular risk or where weight loss is a priority.
Click to open Pubmed Article:
Journal title: Australian journal of general practice
Volume: 51
Pages: 513-518
Publication Date: 2022-07-01
Type: Journal Article
DOI: 10.31128/AJGP-07-21-6057
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.

Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing


PubMed References

Who's citing